The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of crizotinib in patients with MET amplification and MET exon 14 deletion: Results from NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocols C1 and C2.
 
Niamh Coleman
No Relationships to Disclose
 
Zihan Wei
No Relationships to Disclose
 
David S. Hong
Stock and Other Ownership Interests - MolecularMatch; OncoResponse; Telperian
Consulting or Advisory Role - Acuta; Adaptimmune; Alkermes; Alphasights; Amgen; AUM Biosciences; Axiom Biotechnologies; Baxter; Bayer; Boxer Capital; Bridgebio; COG; Cor2Ed; Cowen; EcoR1 Capital; Genentech; Gennao Bio; Gerson Lehrman Group; Gilead Sciences; GroupH; Guidepoint Global; HCW Precision; Immunogen; Infinity Pharmaceuticals; Janssen; Liberum; MedaCorp; Medscape; Numab; Oncologia Brasil; Pfizer; Pharma Intelligence; Precision Oncology Experimental Therapeutics; Prime Oncology; RAIN; ST Cube; Takeda; Tavistock Life Sciences; Trieza Therapeutics; Turning Point Therapeutics; WebMD; YingLing Pharma; ZIOPHARM Oncology
Research Funding - Abbvie (Inst); Adaptimmune (Inst); Adlai Nortye (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol Myers Squibb (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Eisai (Inst); Endeavor BioMedicines (Inst); Erasca, Inc (Inst); F. Hoffmann LaRoche (Inst); Fate Therapeutics (Inst); Genentech (Inst); Genmab (Inst); Ignyta (Inst); Infinity Pharmaceuticals (Inst); Kite, a Gilead company (Inst); Kyowa (Inst); Lilly (Inst); Loxo (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); Mologen (Inst); National Cancer Institute (Inst); Navire (Inst); Novartis (Inst); Numab (Inst); Pfizer (Inst); Pyramid Biosciences (Inst); Seagen (Inst); Takeda (Inst); TCR2 Therapeutics (Inst); Teckro (Inst); Turning Point Therapeutics (Inst); VM Pharma (Inst)
Travel, Accommodations, Expenses - AACR; ASCO; Bayer Schering Pharma; Genmab; Society for Immunotherapy of Cancer; Telperian
 
Edith P. Mitchell
Leadership - Corvus Pharmaceuticals
Honoraria - Exelixis; Sanofi
Consulting or Advisory Role - Bristol Myers Squib; Genentech; Merck; Novartis
Speakers' Bureau - Ipsen
Research Funding - Genentech (Inst); sanofi (Inst)
 
James A. Zwiebel
No Relationships to Disclose
 
Elad Sharon
No Relationships to Disclose
 
Robert James Gray
Research Funding - Abbvie; Agios; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech/Roche; Genomic Health; Genzyme; GlaxoSmithKline; Janssen-Ortho; Merck Sharp & Dohme; Novartis; Onyx; Pfizer; Sanofi; Sequenta; Syndax; Takeda
 
Victoria Wang
No Relationships to Disclose
 
Lisa McShane
No Relationships to Disclose
 
Larry V. Rubinstein
No Relationships to Disclose
 
David R. Patton
No Relationships to Disclose
 
P. Mickey Williams
No Relationships to Disclose
 
James V. Tricoli
No Relationships to Disclose
 
Barbara A. Conley
No Relationships to Disclose
 
Carlos L. Arteaga
Stock and Other Ownership Interests - Provista Diagnostics
Consulting or Advisory Role - Arvinas; Astrazeneca; Athenex; Daiichi Sankyo; Immunomedics; Lilly; Merck; Novartis; Origimed; Puma Biotechnology; Radius Health; Sanofi; Taiho Pharmaceutical
Research Funding - Lilly; Pfizer; Takeda
Other Relationship - Susan G. Komen for the Cure
(OPTIONAL) Uncompensated Relationships - Susan G. Komen for the Cure
 
Lyndsay Harris
Patents, Royalties, Other Intellectual Property - Philips Healthcare
 
Peter J. O'Dwyer
Research Funding - Amgen (Inst); Array BioPharma (Inst); BBI Healthcare (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Five Prime Therapeutics (Inst); Forty Seven (Inst); Genentech (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); Lilly/ImClone (Inst); Minneamrita Therapeutics (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Syndax (Inst); Syndax (Inst); Syndax (Inst); syndax (Inst); Syndax (Inst); Taiho Pharmaceutical (Inst)
Expert Testimony - Dai-ichi Sankyo
 
Alice P. Chen
No Relationships to Disclose
 
Keith Flaherty
Stock and Other Ownership Interests - ALX Oncology; Apricity Health; Checkmate Pharmaceuticals; Clovis Oncology; FOGPharma; Kinnate Biopharma; Loxo; Monopteros Therapeutics; Nextech Invest; Oncoceutics; PIC Therapeutics; Scorpion Therapeutics; Soley Therapeutics; Strata Oncology; Transcode Therapeutics; Tvardi Therapeutics; Vibliome Therapeutics; X4 Pharma; xCures
Consulting or Advisory Role - Debiopharm Group; Immagene; Lilly; Novartis; OmRx Oncology; Oncoceutics; Quanta Therapeutics; Takeda; Tvardi Therapeutics
 
Stanley R. Hamilton
Research Funding - Intima; Minerva Biotechnologies